Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Kymera Therapeutics (KYMR) Net Margin (2019 - 2025)

Historic Net Margin for Kymera Therapeutics (KYMR) over the last 7 years, with Q3 2025 value amounting to 2973.05%.

  • Kymera Therapeutics' Net Margin fell 13027200.0% to 2973.05% in Q3 2025 from the same period last year, while for Sep 2025 it was 124000.84%, marking a year-over-year increase of 1241921000.0%. This contributed to the annual value of 7221.23% for FY2024, which is 70342300.0% down from last year.
  • Latest data reveals that Kymera Therapeutics reported Net Margin of 2973.05% as of Q3 2025, which was down 13027200.0% from 667.6% recorded in Q2 2025.
  • Over the past 5 years, Kymera Therapeutics' Net Margin peaked at 193.43% during Q4 2024, and registered a low of 2973.05% during Q3 2025.
  • Moreover, its 5-year median value for Net Margin was 296.75% (2025), whereas its average is 517.53%.
  • Per our database at Business Quant, Kymera Therapeutics' Net Margin soared by 5129900bps in 2021 and then plummeted by -13027200bps in 2025.
  • Kymera Therapeutics' Net Margin (Quarter) stood at 222.88% in 2021, then rose by 3bps to 216.03% in 2022, then surged by 86bps to 30.01% in 2023, then soared by 745bps to 193.43% in 2024, then crashed by -1637bps to 2973.05% in 2025.
  • Its last three reported values are 2973.05% in Q3 2025, 667.6% for Q2 2025, and 296.75% during Q1 2025.